Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Werner Poewe

Showing results (61-70 of 602) with videos related to

Pageof 61
Sort By:
The Lancet. Neurology|October 22, 2021
Amantadine in the treatment of Parkinson's disease and other movement disordersOlivier Rascol, Margherita Fabbri, Werner Poewe
Drugs|May 20, 2026
Recent Developments in the Drug Treatment of Parkinson's DiseaseSimon Leiter, Philipp Mahlknecht, Werner Poewe
Current Opinion in Neurology|May 18, 2011
New insights into atypical parkinsonismGregor K Wenning, Florian Krismer, Werner Poewe
Experimental Neurology|January 29, 2008
Rasagiline is neuroprotective in a transgenic model of multiple system atrophyNadia Stefanova, Werner Poewe, Gregor K Wenning
Movement Disorders : Official Journal of the Movement Disorder Society|August 23, 2018
Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging FeaturesK Ray Chaudhuri, Werner Poewe, David Brooks
Clinical Interventions in Aging|April 14, 2012
Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's diseaseEva-Maria Hametner, Klaus Seppi, Werner Poewe
Movement Disorders : Official Journal of the Movement Disorder Society|August 11, 2005
Therapeutic strategies in multiple system atrophyGregor K Wenning, Felix Geser, Werner Poewe
Movement Disorders : Official Journal of the Movement Disorder Society|July 11, 2024
Clinical Trials in Times of War: A Testament to Human Resilience and DedicationJoaquim J Ferreira, Olivier Rascol, Werner Poewe
Expert Opinion on Drug Safety|April 4, 2012
Drug safety evaluation of rotigotineFabienne Stephanie Sprenger, Klaus Seppi, Werner Poewe
The Lancet. Neurology|February 11, 2014
Rifampicin for multiple system atrophyGregor K Wenning, Florian Krismer, Werner Poewe
Pageof 61

Showing results (61-70 of 602) with videos related to

Sort By:
Pageof 61
The Lancet. Neurology|October 22, 2021
Amantadine in the treatment of Parkinson's disease and other movement disordersOlivier Rascol, Margherita Fabbri, Werner Poewe
Drugs|May 20, 2026
Recent Developments in the Drug Treatment of Parkinson's DiseaseSimon Leiter, Philipp Mahlknecht, Werner Poewe
Current Opinion in Neurology|May 18, 2011
New insights into atypical parkinsonismGregor K Wenning, Florian Krismer, Werner Poewe
Experimental Neurology|January 29, 2008
Rasagiline is neuroprotective in a transgenic model of multiple system atrophyNadia Stefanova, Werner Poewe, Gregor K Wenning
Movement Disorders : Official Journal of the Movement Disorder Society|August 23, 2018
Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging FeaturesK Ray Chaudhuri, Werner Poewe, David Brooks
Clinical Interventions in Aging|April 14, 2012
Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's diseaseEva-Maria Hametner, Klaus Seppi, Werner Poewe
Movement Disorders : Official Journal of the Movement Disorder Society|August 11, 2005
Therapeutic strategies in multiple system atrophyGregor K Wenning, Felix Geser, Werner Poewe
Movement Disorders : Official Journal of the Movement Disorder Society|July 11, 2024
Clinical Trials in Times of War: A Testament to Human Resilience and DedicationJoaquim J Ferreira, Olivier Rascol, Werner Poewe
Expert Opinion on Drug Safety|April 4, 2012
Drug safety evaluation of rotigotineFabienne Stephanie Sprenger, Klaus Seppi, Werner Poewe
The Lancet. Neurology|February 11, 2014
Rifampicin for multiple system atrophyGregor K Wenning, Florian Krismer, Werner Poewe
Pageof 61